The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure
Sponsored by Synvista Therapeutics, Inc
About this trial
Last updated 15 years ago
Study ID
ALT-711-0527
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
Yes
Accepting
19+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 16 years ago
What is this trial about?
Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play
a role in the development and progression of heart failure. The AGE-crosslink breaker
Alagebrium (ALT-711) improved cardiac function and symptoms in experimental and small
human heart failure studies. These results have not yet been confirmed in a randomized
controlled clinical trial.
What are the participation requirements?
Inclusion Criteria
- NYHA II-IV heart failure
- Echocardiographic ejection fraction ≤ 40%
- Duration of heart failure > 3 months
- Stable heart failure medical therapy for > 1 months
Exclusion Criteria
- History of myocardial infarction in previous 6 months
- History of stroke in previous 6 months
- Clinically significant renal, liver, pulmonary,or hematological disease
- Active and or treated malignancies within 12 months
- Uncontrolled diabetes mellitus